Biopharm Company Video Updates From Pennytobuck.com - Pwrm.ob, Prot.ob, Gern

___

___

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, reported that Power3 delivered four poster presentations at the 2010 International Conference on Alzheimers Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3s diagnostic test, and focused on Power3s Alzheimers disease blood serum biomarkers, test and clinical validation trials.

According to recent estimates, as many as 2.4 million to 4.5 million Americans have Alzheimers disease (AD). Unless the disease can be effectively treated or prevented, the number of people with AD will increase significantly if current population trends continue. Thats because the risk of AD increases with age, and the U.S. population is aging. The number of people age 65 and older is expected to grow from 39 million in 2008 to 72 million in 2030, and the number of people with AD doubles for every 5-year interval beyond age 65.

Power3 has filed several patent applications for its NuroPro technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimers disease, Parkinsons disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrigs disease).

To learn more about visit: http://www.power3medical.com

********************

Proteonomix, Inc., PROT.OB is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.

PROT reported further developments with its Joint Venture Company, XGEN Medical LLC (XGen) towards implementing operations in the United Arab Emirates (U.A.E.).

PROT is the majority shareholder in XGen with the balance held by an anonymous investor group. (51% by PROT and 49% by the Investor Group)

PROTs personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting Proteonomix personnel on Jumeira 2.

During initial meetings, it was mutually decided to open a local subsidiary corporation in the Dubai free zone. This wholly owned subsidiary will be the vehicle to conduct business in the GCC countries.

XGen has filed the corporate papers and has established banking relations with a local bank both for receipt of the initial investment of $5 million and towards further financing expanded services in the region. The Ramadan holiday has slowed progress slightly on these corporate formalities, but full operation of the subsidiary and bank accounts are expected to complete within 30 days.

It was further announced that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with Proteonomix cellular material. Discussions are now further encompassing both the construction of XGens own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of PROTs proprietary cellular materials for treatment of disease.

More about PROT at www.proteonomix.com

****************************

Geron Corporation (Nasdaq:GERN) announced recently that the company has entered into a collaboration with University Campus Suffolk (UCS) in the U.K. to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

The development program will be led by Professor Brendon Noble, recently appointed to UCS as Head of the School of Health, Science and Social Care. Professor Noble was previously at the University of Edinburgh. The project will be based within the new biotechnology unit at UCS, which has been supported by Suffolk County Council and the East of England Development Agency. The program will be jointly funded by Geron and UCS. UCS will provide facilities and equipment for the project. Geron will fund the direct costs of the development work at UCS.

Preclinical studies conducted by Professor Nobles group have shown that injection of hESC-derived chondrocytes (GRNCHND1) into damaged cartilage of the knee joint of immunocompetent rats produced well-integrated cartilage showing full repair of the lesion for at least nine months.

The research in the U.K. has demonstrated that hESC-derived chondrocytes can generate cartilage that appears virtually indistinguishable from host tissue within months after implantation in damaged tissue in a rodent model, said Jane S. Lebkowski, Gerons senior vice president and chief scientific officer, regenerative medicine. Current studies are being conducted in a large animal model to assess cartilage repair and function in a model resembling cartilage damage in the human knee. The next phase of the program will involve development of scaled manufacturing of the chondrocytes to support preclinical studies and eventual clinical testing.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers. Geron is also a world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first such product to enter clinical development.

For more information, visit www.geron.com

******************************************************************

For FREE Daily Stock Alerts & Updates Sign-up At: http://pennytobuck.com/signup

******************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Each advertising commitment has now expired. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

by: Bill Pennyman

POST COMMENT

Footage Video Trailers Ad Filmmaking In Mumbai How To Burn Mp4 (mpeg-4) Videos To A Dvd? How To Import Kodak Video To Final Cut Pro And Edit Kodak Video With Final Cut Pro How To Get More Traffic From Videos -- Traffic Voodoo 2.0 flip video to 3gp converter M3 Navigator Predicts DOW Crumble? [video] Free Video Gaming Video Editing Basics myvideotalk, myvideotalk, omg, myvidetalk, myvideotalk Ping Pong Videos Teach Skills You Need to Master Capture Thrilling Underwater Videos with Your Flip Ultra HD Camcorder Video Squeeze Pages Are Better Than Texts Video Squeeze Pages- 3 Steps To Success